Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT04532346
- Locations
- 🇨🇳
Children's hospital of Fudan University, Shanghai, Shanghai, China
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 5
- Registration Number
- NCT04527549
- Locations
- 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸Bethesda North Hospital, Cincinnati, Ohio, United States
🇺🇸TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Emory University
- Target Recruit Count
- 12
- Registration Number
- NCT04524702
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hosptial, Atlanta, Georgia, United States
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 66
- Registration Number
- NCT04523857
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Baqiyatallah Medical Sciences University
- Registration Number
- NCT04466280
- Locations
- 🇮🇷
Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of
Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Hospital Alemão Oswaldo Cruz
- Target Recruit Count
- 1372
- Registration Number
- NCT04466540
- Locations
- 🇧🇷
Instituto da Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil
🇧🇷Casa de Caridade de Carangola, Carangola, Minas Gerais, Brazil
🇧🇷Centro de Pesquisas Clínicas Dr. Marco Mota HCOR, Maceió, Alagoas, Brazil
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Ravi Amaravadi, MD
- Target Recruit Count
- 94
- Registration Number
- NCT04464759
- Locations
- 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of Combination Therapies to Treat COVID-19 Infection
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- ProgenaBiome
- Registration Number
- NCT04459702
- Locations
- 🇺🇸
ProgenaBiome, Ventura, California, United States
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Qassim University
- Target Recruit Count
- 200
- Registration Number
- NCT04460547
Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 28
- Registration Number
- NCT04458948
- Locations
- 🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.